Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | INSR | P06213 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | ROS1 | P08922 | 2/20 | 0.44 |
| ▸ | FGR | P09769 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | TIE1 | P35590 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765977 | 0.88 | IRAK4 (0.39) | NTRK1 | |
| SCHEMBL21752812 | 0.88 | IRAK4 (0.39) | NTRK1 | |
| SCHEMBL30032848 | 0.88 | IRAK4 (0.39) | NTRK1 | |
| SCHEMBL21752837 | 0.86 | NTRK1 (0.45) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL21752895 | 0.86 | NTRK1 (0.54) | NTRK1 | |
| SCHEMBL21765970 | 0.86 | NTRK1 (0.54) | NTRK1 | |
| SCHEMBL21752904 | 0.84 | NTRK1 (0.50) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL23761835 | 0.84 | NTRK1 (0.39) | NTRK1 | |
| SCHEMBL23761658 | 0.83 | NTRK1 (0.49) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL30056738 | 0.83 | NTRK1 (0.49) | NTRK1NTRK2NTRK3JAK2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805062-B | Imidazo [1,2-b ] pyridazines as Trk inhibitors | 博善人工智能生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4093404-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BenevolentAI Bio Limited (GB) | 2022-11-30 | — | — | EP | disclosed |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BenevolentAl Bio Limited (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BenevolentAl Bio Limited (GB) | 2021-08-19 | — | — | US | disclosed |
| WO-2021148805-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2021-07-29 | — | — | WO | disclosed |
| EP-3840832-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BenevolentAI Bio Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020039209-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | TNK2, TNIK, TNK1 | NTRK1 15/4885NTRK2 16/4885NTRK3 19/4885 |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | MUSK, TPM3, CSNK1A1 | NTRK1 6/4885NTRK2 7/4885NTRK3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.